The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or Lymphoma
Abstract
Purpose: The objective of this study was to define the maximum-tolerated dose (MTD), the recommended phase II dose, the dose-limiting toxicity, and determine the pharmacokinetic (PK) and pharmacodynamic profiles of MS-275. Patients and Methods: Patients with advanced solid tumors or lymphoma were treated with MS-275 orally initially on a once daily × 28 every 6 weeks (daily) and later on once every-14-days (q14-day) schedules. The starting dose was 2 mg/m 2 and the dose was escalated in three- to six-patient cohorts based on toxicity assessments. Results: With the daily schedule, the MTD was exceeded at the first dose level. Preliminary PK analysis suggested the half-life of MS-275 in humans was 39 to 80 hours, substantially longer than predicted by preclinical studies. With the q14-day schedule, 28 patients were treated. The MTD was 10 mg/m 2 and dose-limiting toxicities were nausea, vomiting, anorexia, and fatigue. Exposure to MS-275 was dose dependent, suggesting linear PK. Increased histone H3 acetylation in peripheral-blood mononuclear-cells was apparent at all dose levels by immunofluorescence analysis. Ten of 29 patients remained on treatment for ≥ 3 months. Conclusion: The MS-275 oral formulation on the daily schedule was intolerable at a dose and schedule explored. The q14-day schedule is reasonably well tolerated. Histone deacetylase inhibition was observed in peripheral-blood mononuclear-cells. Based on PK data from the q14-day schedule, a more frequent dosing schedule, weekly × 4, repeated every 6 weeks is presently being evaluated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866
Yoshida, M., Kijima, M., Akita, M., & Beppu, T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44885-x · Cited by 1,854
A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p
Taunton, J., Hassig, C. A., & Schreiber, S. L. (1996) · Science · doi:10.1126/science.272.5260.408 · Cited by 1,829
Retinoblastoma protein recruits histone deacetylase to repress transcription
Brehm, A., Miska, E. A., McCance, D. J., Reid, J. L., Bannister, A. J., & Kouzarides, T. (1998) · Nature · doi:10.1038/35404 · Cited by 1,230
Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells
Marks, P. A., Richon, V. M., & Rifkind, R. A. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1210 · Cited by 1,157
Xue, Y., Wong, J., Moreno, G. T., Young, M. K., Côté, J., & Wang, W. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80299-3 · Cited by 985
Rb Interacts with Histone Deacetylase to Repress Transcription
Luo, R. X., Postigo, A. A., & Dean, D. C. (1998) · Cell · doi:10.1016/s0092-8674(00)80940-x · Cited by 960
Histone Deacetylases Associated with the mSin3 Corepressor Mediate Mad Transcriptional Repression
Laherty, C. D., Yang, W.-M., Sun, J.-M., Davie, J. R., Seto, E., & Eisenman, R. N. (1997) · Cell · doi:10.1016/s0092-8674(00)80215-9 · Cited by 938
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., & Marks, P. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3003 · Cited by 914
Zhang, Y., LeRoy, G., Seelig, H.-P., Lane, W. S., & Reinberg, D. (1998) · Cell · doi:10.1016/s0092-8674(00)81758-4 · Cited by 816
Three proteins define a class of human histone deacetylases related to yeast Hda1p
Grozinger, C. M., Hassig, C. A., & Schreiber, S. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.4868 · Cited by 770
Yoshida, M., Horinouchi, S., & Beppu, T. (1995) · BioEssays · doi:10.1002/bies.950170510 · Cited by 713
Regulation of activity of the transcription factor GATA-1 by acetylation
Boyes, J., Byfield, P., Nakatani, Y., & Ogryzko, V. (1998) · Nature · doi:10.1038/25166 · Cited by 694
Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T., & Nakanishi, O. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4592 · Cited by 694
Class II histone deacetylases: versatile regulators
Verdin, E., Dequiedt, F., & Kasler, H. G. (2003) · Trends in Genetics · doi:10.1016/s0168-9525(03)00073-8 · Cited by 664
Kelly, W. K., Richon, V. M., O’Connor, O. A., Curley, T., MacGregor‐Cortelli, B., Tong, W. P., Klang, M. G., Schwartz, L. B., Richardson, S., Rosa, E., et al. (2003) · PubMed · Cited by 624
Histone acetylases and deacetylases in cell proliferation
Kouzarides, T. (1999) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)80006-9 · Cited by 601
Acetylation of general transcription factors by histone acetyltransferases
Imhof, A., Yang, X.-J., Ogryzko, V. V., Nakatani, Y., Wolffe, A. P., & Ge, H. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00296-x · Cited by 586
HDAC4 deacetylase associates with and represses the MEF2 transcription factor
Miska, E. A. (1999) · The EMBO Journal · doi:10.1093/emboj/18.18.5099 · Cited by 555
Kijima, M., Yoshida, M., Sugita, K., Horinouchi, S., & Beppu, T. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41547-5 · Cited by 514
Sandor, V. A., Bakke, S., Robey, R. W., Kang, M. H., Blagosklonny, M. V., Bender, J., Brooks, R. A., Piekarz, R., Tucker, E. E., Figg, W. D., et al. (2002) · PubMed · Cited by 502
Self-citationFR901228, a Potent Antitumor Antibiotic, Is a Novel Histone Deacetylase Inhibitor
Nakajima, H., Kim, Y. B., Terano, H., Yoshida, M., & Horinouchi, S. (1998) · Experimental Cell Research · doi:10.1006/excr.1998.4027 · Cited by 487
Kao, H.-Y., Downes, M., Ordentlich, P., & Evans, R. M. (2000) · Genes & Development · doi:10.1101/gad.14.1.55 · Cited by 424
Ryan, R. F., Schultz, D. C., Ayyanathan, K., Singh, P. B., Friedman, J. R., Fredericks, W. J., & Rauscher, F. J. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.6.4366 · Cited by 387
A new antifungal antibiotic, trichostatin.
TSUJI, N., KOBAYASHI, M., NAGASHIMA, K., WAKISAKA, Y., & KOIZUMI, K. (1976) · The Journal of Antibiotics · doi:10.7164/antibiotics.29.1 · Cited by 341
George, P., Bali, P., Annavarapu, S., Scuto, A., Fiskus, W., Guo, F., Sigua, C., Sondarva, G., Moscinski, L., Atadja, P., et al. (2005) · Blood · doi:10.1182/blood-2004-09-3413 · Cited by 324
Hu, E., Chen, Z., Fredrickson, T., Zhu, Y., Kirkpatrick, R., Zhang, G.-F., Johanson, K., Sung, C.-M., Liu, R., & Winkler, J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m908988199 · Cited by 309
Characterization of a human RPD3 ortholog, HDAC3
Emiliani, S., Fischle, W., Van Lint, C., Al-Abed, Y., & Verdin, E. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.2795 · Cited by 294
Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991-2001
Baker, S. D., Verweij, J., Rowinsky, E. K., Donehower, R. C., Schellens, J. H. M., Grochow, L. B., & Sparreboom, A. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.24.1883 · Cited by 286
Self-citationJaboin, J. J., Wild, J., Hamidi, H., Khanna, C., Kim, C. J., Robey, R. W., Bates, S. E., & Thiele, C. J. (2002) · PubMed · Cited by 247
Clinical pharmacology of sodium butyrate in patients with acute leukemia
Miller, A. A., Kurschel, E., Osieka, R., & Schmidt, C. G. (1987) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(87)90109-x · Cited by 246
Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase
Kim, Y. B., Lee, K.-H., Sugita, K., Yoshida, M., & Horinouchi, S. (1999) · Oncogene · doi:10.1038/sj.onc.1202564 · Cited by 232
Identification of a New Family of Higher Eukaryotic Histone Deacetylases
Verdel, A., & Khochbin, S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.4.2440 · Cited by 230
Dhordain, P., Quief, S., Lantoine, D., Kerckaert, J.-P., Albagli, O., Lin, R. J., & Evans, R. M. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.20.4645 · Cited by 229
A New Family of Human Histone Deacetylases Related toSaccharomyces cerevisiae HDA1p
Fischle, W., Emiliani, S., Hendzel, M. J., Nagase, T., Nomura, N., Voelter, W., & Verdin, E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.17.11713 · Cited by 225
Gilbert, J., Baker, S. D., Bowling, M. K., Grochow, L. B., Figg, W. D., Zabelina, Y., Donehower, R. C., & Carducci, M. A. (2001) · PubMed · Cited by 206
Self-citationCarducci, M. A., Gilbert, J., Bowling, M. K., Noe, D. A., Eisenberger, M. A., Sinibaldi, V. J., Zabelina, Y., Chen, T., Grochow, L. B., & Donehower, R. C. (2001) · PubMed · Cited by 202
Kwon, H. J., Owa, T., Hassig, C. A., Shimada, J., & Schreiber, S. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3356 · Cited by 197
Glick, R. D., Swendeman, S. L., Coffey, D. C., Rifkind, R. A., Marks, P. A., Richon, V. M., & Quaglia, M. P. L. (1999) · PubMed · Cited by 185
Novogrodsky, A., Dvir, A., Ravid, A., Shkolnik, T., Stenzel, K. H., Rubin, A. L., & Zaizov, R. (1983) · Cancer · doi:10.1002/1097-0142(19830101)51:1<9::aid-cncr2820510104>3.0.co;2-4 · Cited by 159
Transcription: Gene control by targeted histone acetylation
Imhof, A., & Wolffe, A. P. (1998) · Current Biology · doi:10.1016/s0960-9822(98)70268-4 · Cited by 155
Conley, B. A., Egorin, M. J., Tait, N. S., Rosen, D. M., Sausville, E. A., Dover, G. H., Fram, R. J., & Echo, D. A. V. (1998) · PubMed · Cited by 155
Self-citationLee, B. I., Park, S. H., Kim, J. W., Sausville, E. A., Kim, H. T., Nakanishi, O., Trepel, J. B., & Kim, S. J. (2001) · PubMed · Cited by 120
Self-citationAnti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate
Qiu, L., Kelso, M. J., Hansen, C. P., West, M. L., Fairlie, D. P., & Parsons, P. G. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690493 · Cited by 115
Cohen, L. A., Amin, S., Marks, P. A., Rifkind, R. A., Desai, D. H., & Richon, V. M. (1999) · PubMed · Cited by 112
Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug
Edelman, M. J., Bauer, K. S., Khanwani, S. L., Tait, N. S., Trepel, J. B., Karp, J. E., Nemieboka, N. N., Chung, E.-J., & Echo, D. V. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0580-5 · Cited by 98
Self-citationPark, S. H., Lee, S. R., Kim, B. C., Cho, E. A., Patel, S. P., Kang, H., Sausville, E. A., Nakanishi, O., Trepel, J. B., Lee, B. I., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106451200 · Cited by 80
Self-citationLong-Term Treatment with Sodium Phenylbutyrate in Ornithine Transcarbamylase-Deficient Patients
Burlina, A., Ogier, H., Korall, H., & Trefz, F. K. (2001) · Molecular Genetics and Metabolism · doi:10.1006/mgme.2001.3156 · Cited by 58
Hwang, K., Acharya, M. R., Sausville, E. A., Zhai, S., Woo, E. W., Venitz, J., Figg, W. D., & Sparreboom, A. (2004) · Journal of Chromatography B · doi:10.1016/j.jchromb.2004.01.023 · Cited by 15
Self-citationIsozyme-selective activity of the HDAC inhibitor MS-275.
Tatamiya, T., Saito, A., Sugawara, T., & Nakanishi, O. (2004) · Cancer Research · Cited by 14
Protein Binding of Anticancer Drugs
Sparreboom, A., & Loos, W. J. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-734-5_12 · Cited by 6
Self-citation
Cited by
Combination therapy in combating cancer
Mokhtari, R. B., Homayouni, T. S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B., & Yeger, H. (2017) · Oncotarget · doi:10.18632/oncotarget.16723 · Cited by 2,543
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
HDAC family: What are the cancer relevant targets?
Witt, O., Deubzer, H. E., Milde, T., & Oehme, I. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.08.016 · Cited by 1,069
Histone Deacetylase Inhibitors in Cancer Therapy
Lane, A. A., & Chabner, B. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1291 · Cited by 874
Metadata
- Authors
- Ryan, Q. C., Headlee, D., Acharya, M., Sparreboom, A., Trepel, J. B., Ye, J., Figg, W. D., Hwang, K., Chung, E. J., Murgo, A., Melillo, G., Elsayed, Y., Monga, M., Kalnitskiy, M., Zwiebel, J., & Sausville, E. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-06-10
- Volume
- 23
- Issue
- 17
- Pages
- 3912-3922
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2157511493
- Cited by
- 411
- References
- 54
- FWCI
- 16.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.